Cargando…
Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea
PURPOSE: Adoptive cell immunotherapy involves an ex vivo expansion of autologous cytokine-induced killer (CIK) cells before their reinfusion into the host. We evaluated the efficacy and safety of CIK cell immunotherapy with radiotherapy-temozolomide (TMZ) for the treatment of newly diagnosed gliobla...
Autores principales: | Kong, Doo-Sik, Nam, Do-Hyun, Kang, Shin-Hyuk, Lee, Jae Won, Chang, Jong-Hee, Kim, Jeong-Hoon, Lim, Young-Jin, Koh, Young-Cho, Chung, Yong-Gu, Kim, Jae-Min, Kim, Choong-Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351686/ https://www.ncbi.nlm.nih.gov/pubmed/27690294 http://dx.doi.org/10.18632/oncotarget.12273 |
Ejemplares similares
-
Efficacy of Cytokine-Induced Killer Cell Immunotherapy for Patients With Pathologically Pure Glioblastoma
por: Han, Myung-Hoon, et al.
Publicado: (2022) -
Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma
por: Kim, Nalee, et al.
Publicado: (2023) -
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
por: Kim, Byung Sup, et al.
Publicado: (2017) -
Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells
por: Kim, Ji Sung, et al.
Publicado: (2016) -
Medication Adherence and the Occurrence of Complications in Patients with Newly Diagnosed Hypertension
por: Kim, Hyun-Jin, et al.
Publicado: (2016)